DAWN
Day One·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
EPS Beats Expectation
FDA Approved
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DAWN
Day One Biopharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that develops therapies & immno-oncology for cancers
2000 Sierra Point Parkway, Suite 501, Brisbane, CA 94005
--
Day One Biopharmaceuticals, Inc., was incorporated in Delaware in November 2018 as Hero Therapeutics Holding Company, LLC. Subsequently, the Company changed its name to Day One Therapeutics Holding Company, LLC in December 2018 and to Day One Biopharmaceuticals Holding Company, LLC in March 2020. The Company has two subsidiaries: Day One Biopharmaceuticals, Inc. (formerly known as Hero Therapeutics Inc.), a wholly-owned subsidiary incorporated in Delaware in November 2018, and DOT Therapeutics, Inc., a majority subsidiary incorporated in Delaware in December 2019. They are clinical-stage biopharmaceutical companies that develop and commercialize patient-targeted therapies for all age groups with genetically defined cancers. The company's lead product candidate, DAY101, is an oral, highly selective type II pan-RAF kinase inhibitor with brain permeability.
Earnings Call
Q1/2025
Estimate EPS-0.44
Actual EPS-0.35
Estimate Revenue30.27M
Actual Revenue30.76M
Day One Biopharmaceuticals' Q1 2025: Navigating Key Contradictions in Therapy Duration, Gross Ratios, and Market Dynamics
May 07,2025 07:26
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.34
Actual EPS-0.29
Estimate Revenue34.90M
Actual Revenue33.91M
Day One Biopharmaceuticals' Q2 2025: Unpacking Contradictions in Treatment Durability, Financial Projections, and Growth Trajectory
Aug 05,2025 09:31
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
DAWN has released its 2025 Q3 earnings. EPS was reported at -0.19, versus the expected -0.28, beating expectations. The chart below visualizes how DAWN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
DAWN has released its 2025 Q3 earnings report, with revenue of 39.80M, reflecting a YoY change of -57.56%, and net profit of -19.73M, showing a YoY change of -153.26%. The Sankey diagram below clearly presents DAWN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
